NO20084317L - Metoder for a behandle lupus ved bruk av CD4 antistoff - Google Patents
Metoder for a behandle lupus ved bruk av CD4 antistoffInfo
- Publication number
- NO20084317L NO20084317L NO20084317A NO20084317A NO20084317L NO 20084317 L NO20084317 L NO 20084317L NO 20084317 A NO20084317 A NO 20084317A NO 20084317 A NO20084317 A NO 20084317A NO 20084317 L NO20084317 L NO 20084317L
- Authority
- NO
- Norway
- Prior art keywords
- methods
- antibody
- lupus
- depleting
- administration
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Sammendrag Fremgangsmåter for behandling av lupus som inkluderer systemisk lupus erytematose, kutant lupus erytemetose og lupus nefritt, er tilveiebrakt. Fremgangsmåtene involverer administrasjon av en kombinasjon av et ikke-deplerende CD4-antistoff og en annen forbindelse anvendt klinisk eller eksperimentelt for behandling av lupus. Fremgangsmåter for behandling av lupus nefritt ved administrasjon av et ikke-deplerende CD4antistoff som resulterer i en forbedring i renal funksjon og/eller en reduksjon i proteinuri eller aktiv urinsediment er også tilveiebrakt. Fremgangsmåter for behandling av multippel sklerose ved administrasjon av et ikke-deplerende CD4-antistoff, eventuelt i kombinasjon med en andre forbindelse anvendt klinisk eller eksperimentelt for å behandle MS, er beskrevet. Fremgangsmåter for behandling av transplantatresipienter og subjekter med reumatoid artritt, astma, psoriasis, Crohns sykdom, ulcerativ kolitt og Sjogrens syndrom, er også tilveiebrakt.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78353506P | 2006-03-16 | 2006-03-16 | |
US87388106P | 2006-12-07 | 2006-12-07 | |
PCT/US2007/006443 WO2007109052A2 (en) | 2006-03-16 | 2007-03-14 | Methods of treating lupus using cd4 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20084317L true NO20084317L (no) | 2008-12-09 |
Family
ID=38522934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20084317A NO20084317L (no) | 2006-03-16 | 2008-10-15 | Metoder for a behandle lupus ved bruk av CD4 antistoff |
Country Status (12)
Country | Link |
---|---|
US (1) | US20070218062A1 (no) |
EP (1) | EP2001510A4 (no) |
JP (1) | JP2009530290A (no) |
KR (1) | KR20080112300A (no) |
AU (1) | AU2007227609A1 (no) |
BR (1) | BRPI0708902A2 (no) |
CA (1) | CA2645322A1 (no) |
IL (1) | IL193920A0 (no) |
MX (1) | MX2008011785A (no) |
NO (1) | NO20084317L (no) |
RU (1) | RU2008137765A (no) |
WO (1) | WO2007109052A2 (no) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2008309934B2 (en) | 2007-10-12 | 2014-03-06 | F. Hoffmann-La Roche Ag | Protein expression from multiple nucleic acids |
WO2009121690A1 (en) * | 2008-03-13 | 2009-10-08 | Biotest Ag | Agent for treating disease |
CN102027016A (zh) | 2008-03-13 | 2011-04-20 | 生物测试股份公司 | 一种治疗疾病的试剂 |
RU2540018C2 (ru) * | 2008-03-13 | 2015-01-27 | Биотест Аг | Средство для лечения заболевания |
US20100021460A1 (en) * | 2008-07-15 | 2010-01-28 | Genentech, Inc. | Methods of Treating Autoimmune Diseases Using CD4 Antibodies |
WO2010036706A1 (en) * | 2008-09-23 | 2010-04-01 | The Trustees Of The University Of Pennsylvania | Recombination sequence (rs) rearrangement frequency as a measure of central b cell tolerance |
KR20110061630A (ko) * | 2008-09-29 | 2011-06-09 | 바이오테스트 아게 | 질병 치료용 조성물 |
WO2010040105A2 (en) | 2008-10-02 | 2010-04-08 | Trubion Pharmaceuticals, Inc. | Cd86 antagonist multi-target binding proteins |
EP2352521B1 (en) * | 2008-10-14 | 2020-09-16 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
KR101953075B1 (ko) | 2009-10-07 | 2019-02-27 | 제넨테크, 인크. | 루푸스의 치료, 진단 및 모니터링 방법 |
GB0920944D0 (en) | 2009-11-30 | 2010-01-13 | Biotest Ag | Agents for treating disease |
KR20160129093A (ko) | 2010-03-03 | 2016-11-08 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드를 이용한 루푸스 신장염의 치료 |
DE102011082871A1 (de) * | 2011-09-16 | 2013-03-21 | Florian, Prof. Dr. Lang | Therapeutische und diagnostische Targets für Autoimmunität, inflammatorische Prozesse und/oder immuner Pathogenese und/oder von Erkrankungen, welche auf Autoimmunität, inflammatorische Prozessen und/oder immuner Pathogenese beruhen |
BR112014018485A8 (pt) | 2012-02-03 | 2017-07-11 | Teva Pharma | Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf |
AU2013341506A1 (en) | 2012-11-07 | 2015-06-04 | Teva Pharmaceutical Industries Ltd. | Amine salts of Laquinimod |
SG11201506409RA (en) | 2013-03-14 | 2015-09-29 | Teva Pharma | Crystals of laquinimod sodium and improved process for the manufacture thereof |
CN106132433B (zh) | 2013-12-27 | 2021-04-06 | 国立大学法人大阪大学 | 以il-17a作为靶标的疫苗 |
WO2016174106A1 (en) * | 2015-04-28 | 2016-11-03 | Orphidia Limited | Analyte detection and methods therefor |
KR20190120987A (ko) * | 2018-04-17 | 2019-10-25 | 국립암센터 | 고갈성 항 cd4 단일클론항체를 포함하는 항암 t 세포치료제 보조용 조성물 및 이의 용도 |
TW202321457A (zh) | 2021-08-04 | 2023-06-01 | 美商薩那生物科技公司 | 靶向cd4之病毒載體之用途 |
WO2023114949A1 (en) | 2021-12-16 | 2023-06-22 | Sana Biotechnology, Inc. | Methods and systems of particle production |
WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
WO2024044655A1 (en) | 2022-08-24 | 2024-02-29 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
WO2024064838A1 (en) | 2022-09-21 | 2024-03-28 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US77275A (en) * | 1868-04-28 | Improvement in tee manufacture of packing foe steam-engines | ||
US4381295A (en) * | 1979-04-26 | 1983-04-26 | Ortho Pharmaceutical Corporation | Monoclonal antibody to human helper T cells and methods of preparing same |
US4690905A (en) * | 1983-11-16 | 1987-09-01 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method for removal of human antibodies to native DNA from serum |
US4695459A (en) * | 1984-12-26 | 1987-09-22 | The Board Of Trustees Of Leland Stanford Junior University | Method of treating autoimmune diseases that are mediated by Leu3/CD4 phenotype T cells |
US6685941B1 (en) * | 1988-11-23 | 2004-02-03 | The Regents Of The University Of Michigan | Methods of treating autoimmune disease via CTLA-4Ig |
US5690933A (en) * | 1989-05-31 | 1997-11-25 | Glaxo Wellcome Inc. | Monoclonal antibodies for inducing tolerance |
GB9100741D0 (en) * | 1991-01-14 | 1991-02-27 | Univ London | Treatment of disease |
MX9204374A (es) * | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
US5756096A (en) * | 1991-07-25 | 1998-05-26 | Idec Pharmaceuticals Corporation | Recombinant antibodies for human therapy |
US6136310A (en) * | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
WO1994004188A1 (en) * | 1992-08-21 | 1994-03-03 | Genentech, Inc. | Method for treating an lfa-1-mediated disorder |
WO1998026086A1 (en) * | 1996-12-11 | 1998-06-18 | University Of Florida | Novel methods and compositions for treatment of autoimmune diseases |
US7541443B2 (en) * | 2001-06-14 | 2009-06-02 | Tolerrx, Inc. | Anti-CD4 antibodies |
GB2376466A (en) * | 2001-06-14 | 2002-12-18 | Mark Frewin | TRX1 antibody |
CN1993143A (zh) * | 2004-06-04 | 2007-07-04 | 健泰科生物技术公司 | 用于治疗多发性硬化的方法 |
CA2568336A1 (en) * | 2004-06-04 | 2005-12-22 | Genentech, Inc. | Method for treating lupus |
KR20070036138A (ko) * | 2004-06-22 | 2007-04-02 | 톨러알엑스, 인크. | 영장류에서 관용 유발을 위한 항-cd4 항체를 사용하는최적화 용량 결정 |
-
2007
- 2007-03-14 RU RU2008137765/14A patent/RU2008137765A/ru unknown
- 2007-03-14 AU AU2007227609A patent/AU2007227609A1/en not_active Abandoned
- 2007-03-14 CA CA002645322A patent/CA2645322A1/en not_active Abandoned
- 2007-03-14 KR KR1020087025147A patent/KR20080112300A/ko not_active Application Discontinuation
- 2007-03-14 WO PCT/US2007/006443 patent/WO2007109052A2/en active Application Filing
- 2007-03-14 US US11/724,595 patent/US20070218062A1/en not_active Abandoned
- 2007-03-14 BR BRPI0708902-3A patent/BRPI0708902A2/pt not_active Application Discontinuation
- 2007-03-14 JP JP2009500460A patent/JP2009530290A/ja active Pending
- 2007-03-14 EP EP07753094A patent/EP2001510A4/en not_active Withdrawn
- 2007-03-14 MX MX2008011785A patent/MX2008011785A/es not_active Application Discontinuation
-
2008
- 2008-09-04 IL IL193920A patent/IL193920A0/en unknown
- 2008-10-15 NO NO20084317A patent/NO20084317L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2009530290A (ja) | 2009-08-27 |
WO2007109052A2 (en) | 2007-09-27 |
MX2008011785A (es) | 2008-09-25 |
EP2001510A2 (en) | 2008-12-17 |
RU2008137765A (ru) | 2010-04-27 |
KR20080112300A (ko) | 2008-12-24 |
CA2645322A1 (en) | 2007-09-27 |
AU2007227609A1 (en) | 2007-09-27 |
US20070218062A1 (en) | 2007-09-20 |
WO2007109052A3 (en) | 2008-12-11 |
EP2001510A4 (en) | 2010-06-09 |
IL193920A0 (en) | 2011-08-01 |
BRPI0708902A2 (pt) | 2011-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20084317L (no) | Metoder for a behandle lupus ved bruk av CD4 antistoff | |
NO20090093L (no) | Profylaktisk eller terapeutisk middel for inflammatorisk sykdom | |
NO20080125L (no) | 2,6-kinolinylderivater, fremgangsmater for fremstilling derav og deres anvendelse som medikament | |
TWI455947B (zh) | 拮抗性對抗人的cd40單株抗體 | |
NO20072733L (no) | Doseformer | |
AR093106A1 (es) | Silicato de zirconio microporoso para el tratamiento de la hipercalemia | |
Mansuri et al. | Working memory impairments in children with stuttering | |
EA201790563A8 (ru) | Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой | |
NO20055884L (no) | Asenanin for behandling av schizofreni hos en pasient med overvekt eller predisposisjon for overvekt | |
WO2007127480A3 (en) | Materials and methods to reduce low density lipoprotein cholesterol | |
Li et al. | Water-soluble artemisinin derivatives as promising therapeutic immunosuppressants of autoimmune diseases | |
WO2011084791A3 (en) | Early marker of proteinuria in patients treated with an anti-vegf treatment | |
WO2017126700A9 (ja) | 小胞型ヌクレオチドトランスポーター活性阻害剤 | |
Zoccali | Asymmetric dimethylarginine in end-stage renal disease patients: a biomarker modifiable by calcium blockade and angiotensin II antagonism? | |
Zhong-Lei et al. | Clinical analysis of 91 cases of imported falciparum malaria from Africa | |
Pollenus et al. | CCR2 Is Dispensable for Disease Resolution but Required for the Restoration of Leukocyte Homeostasis Upon Experimental Malaria-Associated Acute Respiratory Distress Syndrome (vol 11, 628643, 2021) | |
Counsell | COVID-19 Brief: How is the disease best treated? Results from the RECOVERY and SOLIDARITY clinical trials provide important answers | |
Park et al. | Outcome of cadaveric kidney transplantation from expanded criteria donors | |
朱诚意 et al. | The evolution of inclusions in high quality GCr15 bearing steels during secondary refining process | |
李哲 et al. | Research progress of HIV broadly neutralizing antibodies | |
Faure et al. | Association non fortuite de lymphome thyroïdien et de thyroïdite d’Hashimoto. Surveillance per-thérapeutique difficile | |
Yang | Adalimumab worth it in Crohn’s | |
Van Pottelbergh et al. | The inclusion criteria most appropriate for chronic kidney failure care trajectories: A critical note on care trajectories | |
Fidai et al. | Daratumumab and red cell serologic testing: a single-institution experience | |
Carlsen | Hepatitis: case report |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |